Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Co. Ltd ADR (TAK)

Takeda Pharmaceutical Co. Ltd ADR (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,069,048
  • Shares Outstanding, K 3,155,700
  • Annual Sales, $ 30,059 M
  • Annual Income, $ 3,534 M
  • 60-Month Beta 1.06
  • Price/Sales 1.77
  • Price/Cash Flow 4.67
  • Price/Book 1.11
Trade TAK with:

Options Overview

Details
  • Implied Volatility 19.42%
  • Historical Volatility 20.57%
  • IV Percentile 1%
  • IV Rank 0.83%
  • IV High 74.63% on 10/30/20
  • IV Low 18.96% on 05/26/21
  • Put/Call Vol Ratio 0.10
  • Today's Volume 3,486
  • Volume Avg (30-Day) 957
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 88,738
  • Open Int (30-Day) 113,495

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.57
  • Growth Rate Est. (year over year) +175,163.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.36 +0.86%
on 07/08/21
17.30 -4.61%
on 07/14/21
-0.33 (-1.96%)
since 06/30/21
3-Month
16.35 +0.89%
on 05/11/21
17.56 -6.04%
on 05/21/21
-0.20 (-1.20%)
since 04/30/21
52-Week
15.30 +7.82%
on 10/30/20
19.97 -17.36%
on 03/22/21
-1.66 (-9.14%)
since 07/30/20

Most Recent Stories

More News
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on the solid first-quarter...

TKPYY : 16.5900 (-0.90%)
TAK : 16.50 (-2.54%)
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company...

TKPYY : 16.5900 (-0.90%)
TAK : 16.50 (-2.54%)
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda's Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,(1) its Phase...

TKPYY : 16.5900 (-0.90%)
TAK : 16.50 (-2.54%)
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders

--a^' 12 Abstracts Presented Across Takeda's Hematology Portfolio and Pipeline Support Takeda's Commitment to Improving Patient Care Today as well as Transforming Future Care

TKPYY : 16.5900 (-0.90%)
TAK : 16.50 (-2.54%)
Takeda Announces the Submission of Its Corporate Governance Report to the Tokyo Stock Exchange

Takeda Pharmaceutical Company Limited ("Takeda") (TOKYO:4502) (NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange ("TSE") in accordance with the regulations*...

TKPYY : 16.5900 (-0.90%)
TAK : 16.50 (-2.54%)
New Data from the Phase 3 HELP Study(TM) Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO(R) (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress

--a^' Final Patient Subgroup Analysis Suggests Reductions of HAE Attacks Across Range of Patient Demographics and Disease Characteristics with TAKHZYRO

TKPYY : 16.5900 (-0.90%)
TAK : 16.50 (-2.54%)
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020

Takeda Pharmaceutical Company Limited ("Takeda") (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the "Annual Report") with...

TKPYY : 16.5900 (-0.90%)
TAK : 16.50 (-2.54%)
Takeda Pharmaceuticals Marks its 240th Founding Anniversary

UAE, /PRNewswire/ -- Takeda Pharmaceuticals Company (TSE: 4502) (NYSE: TAK) ("Takeda"), a global, values-based, R&D-driven biopharmaceutical company, headquartered in , is celebrating its 240 founding...

TAK : 16.50 (-2.54%)
Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community

UAE, /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) has introduced the  platform, an award-winning, immersive simulation program to promote greater awareness and empathy for patients with Inflammatory...

TKPHF : 33.4300 (+0.03%)
TAK : 16.50 (-2.54%)
Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today at the American Transplant Congress (ATC) 2021 Virtual Connect presented results from a new subgroup analysis of SOT recipients...

TKPYY : 16.5900 (-0.90%)
TAK : 16.50 (-2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 17.20
2nd Resistance Point 17.02
1st Resistance Point 16.76
Last Price 16.50
1st Support Level 16.32
2nd Support Level 16.14
3rd Support Level 15.88

See More

52-Week High 19.97
Fibonacci 61.8% 18.18
Fibonacci 50% 17.63
Fibonacci 38.2% 17.08
Last Price 16.50
52-Week Low 15.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar